Information Provided By:
Fly News Breaks for February 6, 2019
NVS, CBMG
Feb 6, 2019 | 17:08 EDT
Baird analyst Madhu Kumar initiated Cellular Biomedicine (CBMG) with an Outperform rating and a price target of $26. The analyst says the company's manufacturing capacity in cell therapy provide it with an edge in the "underappreciated China market", while its partnership with Novartis' (NVS) Kymriah in China validates its cell therapy manufacturing prowess. Given the multiple cell therapies expected in the next 12 months, Kumar says Cellular Biomedicine "could have a panoply of shots on goal over the coming year."
News For CBMG;NVS From the Last 2 Days
NVS
NVS
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
NVS
NVS
NVS
NVS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.